Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.50p -4.41% 227.50p 225.00p 230.00p 240.00p 227.50p 240.00p 73,142 16:11:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -17.2 -45.2 - 72

ReNeuron Group plc Jefferies 2019 Global Healthcare Conference

31/05/2019 7:00am

RNS Non-Regulatory


TIDMRENE

ReNeuron Group plc

31 May 2019

 
  31 May 2019    AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or the "Company")

Jefferies 2019 Global Healthcare Conference

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that the Company's management team will be participating in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday 4 June 2019 in New York City.

For further information on the conference, please visit the following link: Jefferies 2019 Global Healthcare Conference

ENDS

 
 Contacts: 
  ReNeuron                                           +44 (0) 20 3819 8400 
 Olav Hellebø, Chief Executive Officer 
 Michael Hunt, Chief Financial Officer 
  Buchanan (UK Media/Investor Relations)             +44 (0) 20 7466 5000 
 Mark Court, Sophie Wills, Tilly Abraham 
  Argot Partners (US Media/Investor Relations)       +1 212 600 1902 or 
   Claudia Styslinger, David Rosen                    email 
                                                      claudia@argotpartners.com 
 
 Stifel Nicolaus Europe Limited (NOMAD and 
  Joint Broker) 
  Jonathan Senior, Stewart Wallace, Ben Maddison    +44 (0) 20 7710 7600 
  N+1 Singer (Joint Broker) 
   Aubrey Powell, Mark Taylor                        +44 (0) 20 7496 3000 
 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRACKDDPPBKKNPN

(END) Dow Jones Newswires

May 31, 2019 02:00 ET (06:00 GMT)

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190722 23:17:10